期刊
WILEY INTERDISCIPLINARY REVIEWS-RNA
卷 12, 期 4, 页码 -出版社
WILEY
DOI: 10.1002/wrna.1641
关键词
gene expression; nonsense mutation; nonsense suppression therapy; nonsense suppressor tRNA; premature termination codon mutations; readthrough; translation
类别
资金
- Cystic Fibrosis Foundation [PORTER20F0, LUECK18GO]
- Vertex Pharmaceuticals
Nonsense mutations create defective truncated proteins by changing amino acid codons. While most PTC therapeutics focus on promoting PTC read-through, there is a need for agents that can recode PTCs with the correct amino acids.
Nonsense mutations change an amino acid codon to a premature termination codon (PTC) generally through a single-nucleotide substitution. The generation of a PTC results in a defective truncated protein and often in severe forms of disease. Because of the exceedingly high prevalence of nonsense-associated diseases and a unifying mechanism, there has been a concerted effort to identify PTC therapeutics. Most clinical trials for PTC therapeutics have been conducted with small molecules that promote PTC read through and incorporation of a near-cognate amino acid. However, there is a need for PTC suppression agents that recode PTCs with the correct amino acid while being applicable to PTC mutations in many different genomic landscapes. With these characteristics, a single therapeutic will be able to treat several disease-causing PTCs. In this review, we will focus on the use of nonsense suppression technologies, in particular, suppressor tRNAs (sup-tRNAs), as possible therapeutics for correcting PTCs. Sup-tRNAs have many attractive qualities as possible therapeutic agents although there are knowledge gaps on their function in mammalian cells and technical hurdles that need to be overcome before their promise is realized. This article is categorized under: RNA Processing > tRNA Processing Translation > Translation Regulation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据